Tk2 loss drives mitochondrial failure in frequent epilepsy seizures
Tk2 deficiency was closely linked to higher seizure frequency across multiple epilepsy types and brain regions.
News
-
-
Clinical trial in Spain to evaluate doxecitin and doxribtimine in TK2d
A clinical trial in Spain aims to study the safety and efficacy of doxecitin and doxribtimine in adult patients with TK2d.
-
Patient with rare muscle disease treated with their own stem cells
Researchers treated the first patient with a rare mitochondrial muscle disease in the same class as TK2d using the patient’s own stem cells.
-
Study: Patients treated with Kygevvi saw a reduced risk of death
Patients who received a newly-approved drug for TK2d had much lower rates of death than patients who were not.
-
Review: Experimental therapy significantly lowers death risk in TK2d
Treatment with pyrimidine nucleos(t)ides was associated with a dramatic reduction in the risk of death compared with no treatment in TK2d.
-
FDA approves first and only drug to treat TK2d
The FDA has approved Kygevvi™ (doxecitine and doxribtimine) for children and adults with Tk2d, making it the first treatment for the disease.